Blockade of TGF-β signaling with novel synthetic antibodies limits immune exclusion and improves chemotherapy response in metastatic ovarian cancer models

References

• Kohn EC, Ivy SP. Whence High-Grade Serous Ovarian Cancer. American Society of Clinical Oncology Educational Book American Society of Clinical Oncology Meeting 2017; 37:443–448. doi:10.14694/EDBK_174718.
   PubMedGoogle Scholar
• Singh N, McCluggage WG, Gilks CB. High-grade serous carcinoma of tubo-ovarian origin: recent developments. Histopathol 2017; 71:339–356. doi:10.1111/his.13248.
   PubMed Web of Science ®Google Scholar
• Marcus CS, Maxwell GL, Darcy KM, Hamilton CA, McGuire WP. Current approaches and challenges in managing and monitoring treatment response in ovarian cancer. J Cancer 2014; 5:25–30. doi:10.7150/jca.7810.
   PubMed Web of Science ®Google Scholar
• Cao L, Shao M, Schilder J, Guise T, Mohammad KS, Matei D. Tissue transglutaminase links TGF-beta, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer. Oncogene 2012; 31:2521–2534. doi:10.1038/onc.2011.429.
   PubMed Web of Science ®Google Scholar
• Rafehi S, Ramos Valdes Y, Bertrand M, McGee J, Prefontaine M, Sugimoto A, DiMattia GE, Shepherd TG. TGFbeta signaling regulates epithelial-mesenchymal plasticity in ovarian cancer ascites-derived spheroids. Endocrine Cancer 2016; 23:147–159. doi:10.1530/ERC-15-0383
   PubMed Web of Science ®Google Scholar
• Rodriguez GC, Haisley C, Hurteau J, Moser TL, Whitaker R, Bast RC, Jr., Stack MS. Regulation of invasion of epithelial ovarian cancer by transforming growth factor-beta. Gynecol Oncol 2001; 80:245–253. doi:10.1006/gyno.2000.6042
   PubMed Web of Science ®Google Scholar
• Massague J. TGFbeta signalling in context. Nature Rev 2012; 13:616–630. doi:10.1038/nrm3434.
   Google Scholar
• Colak S, Ten Dijke P. Targeting TGF-beta Signaling in Cancer. Trends Cancer 2017; 3:56–71. doi:10.1016/j.trecan.2016.11.008.
   PubMed Web of Science ®Google Scholar
• Santibanez JF, Obradovic H, Kukolj T, Krstic J. Transforming growth factor-beta, matrix metalloproteinases, and urokinase-type plasminogen activator interaction in the cancer epithelial to mesenchymal transition. Dev Dyn 2018; 247:382–395. doi:10.1002/dvdy.24554.
   PubMed Web of Science ®Google Scholar
• Heneberg P. Paracrine tumor signaling induces transdifferentiation of surrounding fibroblasts. Crit Rev Oncol Hematol 2016; 97:303–311. doi:10.1016/j.critrevonc.2015.09.008.
   PubMed Web of Science ®Google Scholar
• Tauriello DVF, Palomo-Ponce S, Stork D, Berenguer-Llergo A, Badia-Ramentol J, Iglesias M, Sevillano M, Ibiza S, Canellas A, Hernando-Momblona X, et al. TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis. Nature 2018; 554:538–543. doi:10.1038/nature25492
   PubMed Web of Science ®Google Scholar
• Lan Y, Zhang D, Xu C, Hance KW, Marelli B, Qi J, Yu H, Qin G, Sircar A, Hernandez VM, et al. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-beta. Sci Transl Med 2018; 10 (424).DOI: 10.1126/scitranslmed.aan5488
   Web of Science ®Google Scholar
• Ravi R, Noonan KA, Pham V, Bedi R, Zhavoronkov A, Ozerov IV, Makarev E, Artemov A, Wysocki PT, Mehra R, et al. Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFbeta enhance the efficacy of cancer immunotherapy. Nature Comm 2018; 9:741. doi:10.1038/s41467-017-02696-6
   PubMed Web of Science ®Google Scholar
• Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE III, Koeppen H, Astarita JL, Cubas R, et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 2018; 554:544–548. doi:10.1038/nature25501
   PubMed Web of Science ®Google Scholar
• Katz LH, Li Y, Chen JS, Munoz NM, Majumdar A, Chen J, Mishra L. Targeting TGF-beta signaling in cancer. Exp Op Ther Targets 2013; 17:743–760. doi:10.1517/14728222.2013.782287
   PubMed Web of Science ®Google Scholar
• de Gramont A, Faivre S, Raymond E. Novel TGF-beta inhibitors ready for prime time in onco-immunology. Oncoimmunol 2017; 6:e1257453. doi:10.1080/2162402X.2016.1257453.
   PubMed Web of Science ®Google Scholar
• Herbertz S, Sawyer JS, Stauber AJ, Gueorguieva I, Driscoll KE, Estrem ST, Cleverly AL, Desaiah D, Guba SC, Benhadji KA, et al. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des Dev Ther 2015; 9:4479–4499.
   PubMed Web of Science ®Google Scholar
• Persson H, Ye W, Wernimont A, Adams JJ, Koide A, Koide S, Lam R, Sidhu SS. CDR-H3 diversity is not required for antigen recognition by synthetic antibodies. J Mol Biol 2013; 425:803–811. doi:10.1016/j.jmb.2012.11.037
   PubMed Web of Science ®Google Scholar
• Lin SW, Lee MT, Ke FC, Lee PP, Huang CJ, Ip MM, Chen L, Hwang JJ. TGFbeta1 stimulates the secretion of matrix metalloproteinase 2 (MMP2) and the invasive behavior in human ovarian cancer cells, which is suppressed by MMP inhibitor BB3103. Clin Exp Met 2000; 18:493–499. doi:10.1023/A:1011888126865
   PubMed Web of Science ®Google Scholar
• Qiu X, Cheng JC, Zhao J, Chang HM, Leung PC. Transforming growth factor-beta stimulates human ovarian cancer cell migration by up-regulating connexin43 expression via Smad2/3 signaling. Cell Signal 2015; 27:1956–1962. doi:10.1016/j.cellsig.2015.07.010.
   PubMed Web of Science ®Google Scholar
• Cho MS, Bottsford-Miller J, Vasquez HG, Stone R, Zand B, Kroll MH, Sood AK, Afshar-Kharghan V. Platelets increase the proliferation of ovarian cancer cells. Blood 2012; 120:4869–4872. doi:10.1182/blood-2012-06-438598
   PubMed Web of Science ®Google Scholar
• Gallop MA, Barrett RW, Dower WJ, Fodor SP, Gordon EM. Applications of combinatorial technologies to drug discovery. 1 Background Peptide Combinatorial Libraries J Med Chem 1994;37:1233–1251.
   Google Scholar
• Walton J, Blagih J, Ennis D, Leung E, Dowson S, Farquharson M, Tookman LA, Orange C, Athineos D, Mason S, et al. CRISPR/Cas9-mediated Trp53 and Brca2 knockout to generate improved murine models of ovarian high grade serous carcinoma. Cancer Res 2016. doi:10.1158/0008-5472.CAN-16-1272.
   Google Scholar
• Baldassarre T, Truesdell P, Craig AW. Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers. Breast Cancer Res 2017; 19:110. doi:10.1186/s13058-017-0900-z.
   PubMed Web of Science ®Google Scholar
• Tiwari N, Gheldof A, Tatari M, Christofori G. EMT as the ultimate survival mechanism of cancer cells. Sem Cancer Biol 2012; 22:194–207. doi:10.1016/j.semcancer.2012.02.013.
   PubMed Web of Science ®Google Scholar
• Chen WF, Gao WD, Li QL, Zhou PH, Xu MD, Yao LQ. SLIT2 inhibits cell migration in colorectal cancer through the AKT-GSK3beta signaling pathway. Intl J Colorectal Dis 2013; 28:933–940. doi:10.1007/s00384-013-1641-9.
   PubMed Web of Science ®Google Scholar
• Zheng L, Xu M, Xu J, Wu K, Fang Q, Liang Y, Zhou S, Cen D, Ji L, Han W, et al. ELF3 promotes epithelial-mesenchymal transition by protecting ZEB1 from miR-141-3p-mediated silencing in hepatocellular carcinoma. Cell Death Dis 2018; 9:387. doi:10.1038/s41419-018-0399-y
   PubMed Web of Science ®Google Scholar
• Shirakihara T, Kawasaki T, Fukagawa A, Semba K, Sakai R, Miyazono K, Miyazawa K, Saitoh M. Identification of integrin alpha3 as a molecular marker of cells undergoing epithelial-mesenchymal transition and of cancer cells with aggressive phenotypes. Cancer Sci 2013; 104:1189–1197. doi:10.1111/cas.12220
   PubMed Web of Science ®Google Scholar
• Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nature Rev Clin Oncol 2017; 14:611–629. doi:10.1038/nrclinonc.2017.44.
   PubMed Web of Science ®Google Scholar
• Tian J, Hachim MY, Hachim IY, Dai M, Lo C, Raffa FA, Ali S, Lebrun JJ. Cyclooxygenase-2 regulates TGFbeta-induced cancer stemness in triple-negative breast cancer. Sci Rep 2017; 7:40258. doi:10.1038/srep40258
   PubMed Web of Science ®Google Scholar
• Rao S, Zaidi S, Banerjee J, Jogunoori W, Sebastian R, Mishra B, Nguyen BN, Wu RC, White J, Deng C, et al. Transforming growth factor-beta in liver cancer stem cells and regeneration. Hepatol Comm 2017; 1:477–493. doi:10.1002/hep4.1062
   PubMedGoogle Scholar
• Chiu WT, Huang YF, Tsai HY, Chen CC, Chang CH, Huang SC, Hsu KF, Chou CY. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells. Oncotarget 2015; 6:2349–2365. doi:10.18632/oncotarget.2957
   PubMedGoogle Scholar
• Bellomo C, Caja L, Moustakas A. Transforming growth factor beta as regulator of cancer stemness and metastasis. Br J Cancer 2016; 115:761–769. doi:10.1038/bjc.2016.255.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Hou X, Evans BJ, VanBlaricom JL, Weroha SJ, Cliby WA. LY2157299 Monohydrate, a TGF-betaR1 Inhibitor, Suppresses Tumor Growth and Ascites Development in Ovarian Cancer. Cancers 2018; 10(8). doi:10.3390/cancers10080260
   Google Scholar
• Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Carcia JR, Zhang L, Burow M, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942–949. doi:10.1038/nm1093
   PubMed Web of Science ®Google Scholar
• Yang L, Pang Y, Moses HL. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 2010; 31:220–227. doi:10.1016/j.it.2010.04.002.
   PubMed Web of Science ®Google Scholar
• Liu VC, Wong LY, Jang T, Shah AH, Park I, Yang X, Zhang Q, Lonning S, Teicher BA, Lee C. Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol 2007; 178:2883–2892.
   PubMed Web of Science ®Google Scholar
• Milne K, Kobel M, Kalloger SE, Barnes RO, Gao D, Gilks CB, Watson PH, Nelson BH. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PloS One 2009; 4:e6412. doi:10.1371/journal.pone.0006412
   PubMed Web of Science ®Google Scholar
• Preston CC, Maurer MJ, Oberg AL, Visscher DW, Kalli KR, Hartmann LC, Goode EL, Knutson KL. The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer. PloS One 2013; 8:e80063. doi:10.1371/journal.pone.0080063
   PubMed Web of Science ®Google Scholar
• Duraiswamy J, Freeman GJ, Coukos G. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res 2013; 73:6900–6912. doi:10.1158/0008-5472.CAN-13-1550.
   PubMed Web of Science ®Google Scholar
• Fellouse FA, Esaki K, Birtalan S, Raptis D, Cancasci VJ, Koide A, Jhurani P, Vasser M, Wiesmann C, Kossiakoff AA, et al. High-throughput generation of synthetic antibodies from highly functional minimalist phage-displayed libraries. J Mol Biol 2007; 373:924–940. doi:10.1016/j.jmb.2007.08.005
   PubMed Web of Science ®Google Scholar
• Rajan S, Sidhu SS. Simplified synthetic antibody libraries. Meth Enzymol 2012; 502:3–23. doi:10.1016/B978-0-12-416039-2.00001-X.
   PubMed Web of Science ®Google Scholar
• Sidhu SS, Li B, Chen Y, Fellouse FA, Eigenbrot C, Fuh G. Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions. J Mol Biol 2004; 338:299–310. doi:10.1016/j.jmb.2004.02.050.
   PubMed Web of Science ®Google Scholar